- Home
- MOLN vs SRG Comparison
MOLN vs SRG Comparison
Compare MOLN & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | SRG |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Switzerland | United States |
| Employees | N/A | 7 |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 166.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MOLN | SRG |
|---|---|---|
| Price | $4.76 | $2.76 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.38 | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 196.4K |
| Earning Date | 03-12-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $318.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.36 | $2.43 |
| 52 Week High | $5.36 | $4.56 |
Technical Indicators
Market Signals| Indicator | MOLN | SRG |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 31.46 |
| Support Level | $3.51 | $2.72 |
| Resistance Level | $5.33 | $3.68 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 51.45 | 14.81 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.